ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

Core Insights - ZYUS Life Sciences Corporation announced favorable preliminary results from its Phase 2a UTOPIA-1 trial, which evaluates Trichomylin® softgel capsules for managing cancer-related pain [1][2] Group 1: Trial Overview - UTOPIA-1 is a single-arm, proof-of-concept study focused on the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain [2] - Preliminary results are based on data from the first 25% of enrolled patients who have completed treatment [2] Group 2: Preliminary Findings - Early data suggest a reduction in average daily pain, pain interference, and pain severity [5] - There was a reduction in opioid dosing for breakthrough pain, indicating potential benefits of Trichomylin® [5] - No serious adverse events related to Trichomylin® softgel capsules were reported, and the capsules were generally well tolerated [5] Group 3: Company Commitment and Future Outlook - The company emphasizes its commitment to developing non-opioid alternatives for pain management and aims to secure regulatory approval for its innovative therapies [3] - The positive preliminary findings reflect over seven years of scientific research and clinical development, reinforcing the potential of Trichomylin® to address cancer-related pain [2][3]